A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years

Internal Medicine

Volumn 51, Issue 16, 2012, Pages 2125-2129

  Maruyama, Yuriko ^a   Hisamatsu, Tadakazu ^a   Matsuoka, Katsuyoshi ^a   Naganuma, Makoto ^a   Inoue, Nagamu ^a   Ogata, Haruhiko ^a   Iwao, Yasushi ^a   Kanai, Takanori ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Infliximab; Intestinal Beh et's disease; Mucosal healing; Sustained deep remission

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; PREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DUODENOSCOPY; ESOPHAGUS INJURY; FEMALE; HUMAN; INTESTINE MUCOSA; MONOTHERAPY; REMISSION; ULCER HEALING;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; C-REACTIVE PROTEIN; COLONOSCOPY; ESOPHAGEAL DISEASES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; PREDNISOLONE; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; ULCER;

EID: 84865138138     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.8005     Document Type: Article

References (26)

1. Garton RA, Ghate JV, Jorizzo JL. Behçet's disease. In: Textbook of Rheumatology. 7th ed. Harris ED Jr, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, Eds. Saunders, Philadelphia, 2005.
2. Krause I, Weinberger A. Behçet's disease. Curr Opin Rheumatol 20: 82-87, 2008, Review.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Current concepts: Behçet disease. New Eng J Med 341: 1284-1291, 1999.
4. Brandt LJ, Boley SJ. Intestinal ischemia. In: Gastrointestinal and Liver Disease. 7th ed. Feldman M, Friedman LS, Sleisenger MH, Eds. Saunders, Philadelphia, 2002.
5. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 42: 737-745, 2007.
6. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728, 2001.
7. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 120: 995-999, 2001.
8. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46: 118-121, 2003.
9. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factoralpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 50: 672-676, 2007.
10. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 22: 24-27, 2007.
11. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 26: 1383-1385, 2007.
12. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 46: 212-215, 2008.
13. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 14: 1259-1264, 2008.
14. Donghi D, Mainetti C. Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatology 220: 282-286, 2010.
15. Mizushima Y. Recent research into Behcet's disease in Japan. Int J Tissue React 10: 59-65, 1988.
16. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G. Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol 30: 157-163, 2011.
17. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5- aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease. J Clin Gastroenterol 30: e38-e45, 2012.
18. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol 95: 2848-2851, 2000.
19. Iida M, Kobayashi H, Matsumoto T, et al. Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum 37: 16-21, 1994.
20. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behçet's disease. Inflamm Bowel Dis 17: 1594-1602, 2011.
21. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 28: 2010 [Epub ahead of print].
22. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.
23. Van Assche G, Magdelaine-Beuzelin C, D'Haens G. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861-1868, 2008.
24. Schnitzler F, Fidder H, Ferrante M. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58: 492-500, 2009.
25. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 15: 1769-1771, 2009.
26. Iwata S, Saito K, Yamaoka K. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21: 184-191, 2011.